Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 29 April 1983:
Vol. 220. no. 4596, pp. 517 - 519
DOI: 10.1126/science.6682245
Prev | Table of Contents | Next

Articles

Science, Vol 220, Issue 4596, 517-519
Copyright © 1983 by American Association for the Advancement of Science

articles

Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma"

V Bertele, A Falanga, M Tomasiak, E Dejana, C Cerletti, and G de Gaetano

Selective pharmacological inhibition of thromboxane A2 synthesis did not prevent arachidonate-induced aggregation of human platelets in vitro. Prevention was instead achieved by a combination of thromboxane A2 inhibitors with low concentrations of aspirin. The latter partially reduced the proaggregatory cyclooxygenase products that accumulated when thromboxane A2 synthesis was blocked. The aspirin concentrations did not affect per se either platelet aggregation or prostacyclin synthesis in cultured human endothelial cells. The combination of thromboxane synthetase inhibitors with low doses of aspirin may offer greater antithrombotic potential than either drug alone.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Inhibition of platelet aggregation by monoclonal antibody reactive with beta 2-microglobulin chain of HLA complex.
R. Curry, R. Messner, and G. Johnson (1984)
Science 224, 509-511
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)